Results 21 to 30 of about 55,357 (215)
Wnt/β-catenin pathway is a key signaling pathway to trastuzumab resistance in gastric cancer cells
BMC Cancer, 2023 Background Trastuzumab is the only approved target agent for the first-line treatment of human epidermal growth factor receptor-2 (HER-2) positive gastric cancer; however, trastuzumab resistance is a major problem in clinical practice.
Yuna Kim +6 more
doaj +1 more source
Chinese Medical Journal, 2022 . Background:. Pertuzumab has been approved for application in China by the National Medical Products Administration, and both national and international guidelines make recommendations for the use of neoadjuvant treatment with trastuzumab or trastuzumab
Yuanjia Cheng +6 more
doaj +1 more source
Cell Death Discovery, 2022 Acquired Trastuzumab resistance is a complicated and disastrous event for HER2-positive gastric cancer (GC). In this study, we successfully established a GC PDX model with Trastuzumab sensitivity (176P) and induced a homologous model with acquired ...
Mengqi Zhang +10 more
doaj +1 more source
Scientific Reports, 2022 Adjuvant trastuzumab has been associated with superior survival in women with ≥ T1c or node-positive HER2-positive early-stage breast cancer; however, there is a lack of phase III trials in women with T1a/bN0 disease.
Sanji Ali +12 more
doaj +1 more source
Systematic Reviews, 2022 Introduction Trastuzumab, as the gold standard for HER2-positive BC treatment, was the first-line HER2 targeted drug. However, some studies reported patients benefited more from lapatinib and lapatinib plus trastuzumab therapy than standard trastuzumab ...
Ye Yuan, Xumei Liu, Yi Cai, Wenyuan Li
doaj +1 more source
Cells, 2022 To improve the efficacy of trastuzumab, it is essential to understand its mechanism of action. One of the significant issues that makes it difficult to determine the precise mechanism of trastuzumab action is the formation of various HER receptor dimers ...
Hamid Maadi, Zhixiang Wang
doaj +1 more source
A Case of Corneal Melting in a Patient with HER2-Positive Breast Cancer
Case Reports in Ophthalmology, 2022 Trastuzumab is the cornerstone treatment for HER2-positive breast cancer. While ocular side effects are more commonly described after the use of the antibody-drug conjugate ado-trastuzumab emtansine, we here describe corneal melting in a 79-year-old ...
Deborah Peeters +3 more
doaj +1 more source
International Journal of Population Data Science, 2017 Objectives In 2001 the Australian government circumvented traditional drug subsidy listing processes to create the Herceptin Program (HP) for HER2 metastatic breast cancer (MBC) patients; in 2006 trastuzumab was subsidised for early breast cancer (EBC ...
Benjamin Daniels, Sallie-Anne Pearson
doaj +1 more source
Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics
Journal of Ovarian Research, 2010 Background Early studies have demonstrated comparable levels of HER2/ErbB2 expression in both breast and ovarian cancer. Trastuzumab (Herceptin), a therapeutic monoclonal antibody directed against HER2, is FDA-approved for the treatment of both early and
Wilken Jason A +2 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Type I interferon (IFN) has been approved as an anticancer agent to treat some malignancies. However, IFNs have a short in vivo half-life, systemic toxicity, and poor biophysical properties, which prevent it from being widely used for cancer therapy ...
Chan Gyu Lee +17 more
doaj +1 more source